Worth reading
49Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
57.2
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 October 2025 to 30 June 2026ConsolidatedJapanese GAAPNet Sales27,415¥ millionYear on year +4.3%Progress 77.0%
Operating profit696¥ millionYear on year +57.2%Progress 96.7%
Ordinary income769¥ millionYear on year +51.2%Progress 93.8%
Net income attributable to owners of the parent538¥ millionYear on year +44.8%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥597.74
Financial position at period-end
Total assets19,693¥ million
of which net assets 8,879 ¥ millionEquity ratio 44.6%vs. prior year-end +1.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueIndustry ¥14,277,831 thousand (YoY +5.3%), Medical ¥11,298,146 thousand (YoY +6.0%), Academia & Life Sciences ¥1,839,049 thousand (YoY -10.8%)
Segment profitIndustry ¥1,373,241 thousand (YoY +12.0%), Medical ¥1,055,681 thousand (YoY +4.8%), Academia & Life Sciences ¥250,424 thousand (YoY +10.3%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥35,600 million (YoY +3.4%)
Operating profit¥720 million (YoY +39.0%)
Ordinary income¥820 million (YoY +37.8%)
Profit attributable to owners of the parent¥510 million (YoY +19.2%)
Net income per share¥543.88
Revision to Earnings ForecastNot disclosed → Net Sales 35,600 / Operating profit 720 / Ordinary income 820 / Profit attributable to owners of the parent 510
Annual Dividend Forecast¥125 → ¥105（-16.0%）
Factors Behind Changes in Business Performance
In the Industry segment, capital investment and increased production at factories contributed to results; in the Medical segment, new and large-scale projects contributed; and in the Academia & Life Sciences segment, deliveries of equipment for large-scale projects contributed.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥12,545 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥619 thousand
Depreciation and amortization¥103,135 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End960,000
Treasury Shares at Period-End59,092
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025 to 30 June 2026 |
| Net Sales | ¥27,415 million (YoY +4.3%) |
| Operating profit | ¥696 million (YoY +57.2%) |
| Ordinary income | ¥769 million (YoY +51.2%) |
| Profit attributable to owners of the parent | ¥538 million (YoY +44.8%) |
| Net income per share | ¥597.74 |
| Equity ratio | End of the current fiscal period 44.6 / End of previous period 43 |
| Total assets | ¥19,693 million |
| Net assets | ¥8,879 million |
| Full-year earnings forecast | Net Sales ¥35,600 million (YoY +3.4%) / Operating profit ¥720 million (YoY +39.0%) / Ordinary income ¥820 million (YoY +37.8%) / Profit attributable to owners of the parent ¥510 million (YoY +19.2%) / Net income per share ¥543.88 |
| Revision to Earnings Forecast | Not disclosed → Net Sales 35,600 / Operating profit 720 / Ordinary income 820 / Profit attributable to owners of the parent 510 |
| Annual Dividend Forecast | ¥125 → ¥105（-16.0%） |
| Segment revenue | Industry ¥14,277,831 thousand (YoY +5.3%), Medical ¥11,298,146 thousand (YoY +6.0%), Academia & Life Sciences ¥1,839,049 thousand (YoY -10.8%) |
| Segment profit | Industry ¥1,373,241 thousand (YoY +12.0%), Medical ¥1,055,681 thousand (YoY +4.8%), Academia & Life Sciences ¥250,424 thousand (YoY +10.3%) |
| Depreciation and amortization | ¥103,135 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥12,545 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥619 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 960,000 |
| Treasury Shares at Period-End | 59,092 |
| Factors Behind Changes in Business Performance | In the Industry segment, capital investment and increased production at factories contributed to results; in the Medical segment, new and large-scale projects contributed; and in the Academia & Life Sciences segment, deliveries of equipment for large-scale projects contributed. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Capital investment and increased production at factories, new and large-scale projects, and deliveries of equipment for large-scale projects contributed to results. The company also strengthened its operating foundation and pursued proactive sales activities in response to changes in the business environment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.